Lb Pharmaceuticals (LBRX) Accumulated Expenses (2024 - 2026)

Lb Pharmaceuticals' Accumulated Expenses history runs 3 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses changed N/A year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $1.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.7 million, up 16.59% from the prior year.
• Accumulated Expenses declined to $1.1 million in Q1 2026 per LBRX's latest filing, from $1.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $3.3 million in Q3 2025 and bottomed at $1.1 million in Q1 2026.
• The 3-year median for Accumulated Expenses is $1.6 million (2024), against an average of $1.9 million.
• Biggest YoY gain for Accumulated Expenses was 16.59% in 2025; the steepest drop was 16.59% in 2025.
• Year by year, Accumulated Expenses stood at $1.4 million in 2024, then grew by 16.59% to $1.7 million in 2025, then plunged by 35.12% to $1.1 million in 2026.
• Per Business Quant, the three latest LBRX Accumulated Expenses figures stand at $1.1 million (Q1 2026), $1.7 million (Q4 2025), and $3.3 million (Q3 2025).